Lupin Extends Timeline For Philippines Subsidiary Acquisition; Completion Expected In July 2026

On Friday, Indian equity benchmarks ended lower, with the benchmark Nifty 50 index declining 1.05 per cent to close at 23,751.50. Pharmaceutical stocks remained in focus amid corporate developments and strategic acquisition updates. In this segment, Lupin informed stock exchanges that it has revised the expected completion timeline for its proposed acquisition of minority shareholding in Multicare Pharmaceuticals Philippines, Inc.

Lupin Revises Completion Timeline

Lupin Limited disclosed that the proposed acquisition of minority shareholding in Multicare Pharmaceuticals Philippines, Inc. is still under process and is now expected to be completed in July 2026, subject to certain closing conditions. The company stated that the transaction, which was earlier expected to conclude by the end of May 2026, requires additional time before completion.

The update was communicated to both BSE and the National Stock Exchange of India in accordance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Background Of The Transaction

Earlier, on April 1, 2026, Lupin had announced that Nanomi B.V., Netherlands, its wholly owned subsidiary, entered into definitive agreements to acquire the minority shareholding held by certain existing shareholders in Multicare Pharmaceuticals Philippines, Inc. Multicare is already a subsidiary of Nanomi, and the proposed transaction is aimed at increasing ownership within the group structure.

While the company has extended the timeline for completion, it has not indicated any change in the structure, scope or terms of the proposed acquisition. The transaction remains subject to fulfilment of customary closing conditions.

Acquisition Process Continues

The latest disclosure confirms that the acquisition process remains active and that Lupin continues to work towards completing the transaction. No financial details relating to the acquisition were disclosed as part of the update.

The company described the disclosure as an update for information and dissemination purposes and reiterated that completion of the transaction is contingent upon meeting the remaining closing requirements.

About Lupin

Lupin Ltd is a Mumbai-headquartered pharmaceutical company engaged in the development, manufacturing and marketing of branded and generic formulations, biotechnology products and active pharmaceutical ingredients (APIs).

Founded by Dr. Desh Bandhu Gupta in 1968 and incorporated in 1983, the company operates across more than 100 markets globally. Lupin has 15 manufacturing facilities and seven research centres worldwide and, as of March 31, 2025, operated through 32 subsidiaries and one joint venture

Disclaimer: This article is for informational purposes only and does not constitute investment advice.